Speaking Engagement

IPOs and Beyond: Tapping into the Public Market’s Capital

19th Annual BIO CEO & Investor Conference

13 Feb 2017 03:30 p.m. - 04:25 p.m.

Waldorf Astoria New York
301 Park Avenue
New York, NY 10022

As biotech IPO activity has cooled from its 2015 peak, companies are more deliberately weighing reverse mergers and other alternatives to benefiting from the capital in public markets. With post-election market uncertainty, does the IPO market for 2017 seek to rise, fall, or stay level? What markers should CEOs watch for to gauge their timing and choices? This session will feature experienced voices for explaining the practical techniques for getting into public markets and what investors are expecting to see in order to win their support.

Moderator: Stephen Thau, Partner, Morrison & Foerster


  • James Cappuccio, Managing Director, Investment Banking, H.C. Wainwright & Co., LLC
  • Brian Hagerty, Senior Director, Head of Healthcare Capital Markets, New York Stock Exchange
  • Douglas E. Onsi, Chief Financial Officer, Leap Therapeutics, Inc.
  • Sapna Srivastava, PhD, former Chief Financial Officer and Chief Strategy Officer, Intellia Therapeutics
  • Nassim Usman, PhD, President and Chief Executive Officer, Catalyst Biosciences


  • Enrico Granata, Partner, Morrison & Foerster
  • Jeffery Bell, Partner, Morrison & Foerster



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.